Minimally invasive percutaneous nephrolithotomy in patients with autosomal dominant polycystic kidney disease and renal stone

doi:10.3877/cma.j.issn.1674-3253.2018.01.008

Abstract

Abstract:

Objective

To evaluate the safety and efficacy of minimally invasive percutaneous nephrolithotomy (MPCNL) in patients with autosomal dominant polycystic kidney disease (ADPKD) and renal stone.

Methods

The clinical data of patients with ADPKD and renal stone who underwent MPCNL in our hospital between January 2006 and December 2015 were analyzed retrospectively.

Results

twenty-seven renal units in 26 patients were included in our study. Twenty-five patients were performed in one stage MPCNL and one patient underwent second-stage MPCNL. The overall stone clearance rate was 88.9% (24/27). Three patients received ESWL because of residual calculi. The mean operation time was (68±34) min (range 20~140 min) and the mean blood loss was (57±49) ml (range 10~250 ml). The mean preoperative creatinine (Cr) and postoperative Cr level were (292±51) μmol/L and (219.8±33.6) μmol/L, (t=2.388, P=0.025). Two cases had fever postoperatively and four cases received blood transfusion because of hemorrhage.

Conclusion

MPCNL is a safe and effective approach for management of renal calculi in patients wih ADPKD.

Key words: APPKD, Renal stone, Minimal invasion, PCNL

Huiming Jiang, Shiwu Yao, Kaihua Zhong, Qiang He, Yifeng Lin, Dejia Guan. Minimally invasive percutaneous nephrolithotomy in patients with autosomal dominant polycystic kidney disease and renal stone[J]. Chinese Journal of Endourology(Electronic Edition), 2018, 12(01): 28-30.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2018.01.008

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2018/V12/I01/28

Figures/Tables 1

References 17

[1]	Mao Z, Xie G, Ong AC. Metabolic abnormalities in autosomal dominant polycystic kidney disease[J]. Nephrol Dial Transplant, 2015, 30(2): 197-203.
[2]	Rangan GK, Lopez-Vargas P, Nankivell BJ, et al. Autosomal dominant polycystic kidney disease: a path forward[J]. Semin Nephrol, 2015, 35(6): 524-537.
[3]	Schrier RW, Brosnahan G, Cadnapaphornchai MA, et al. Predictors of autosomal dominant polycystic kidney disease progression[J]. J Am Soc Nephrol, 2014, 25(11): 2399-2418.
[4]	Nishiura JL, Neves RF, Eloi SR, et al. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients[J]. Clin J Am Soc Nephrol, 2009, 4(4): 838-844.
[5]	Lei M, Zhu W, Wan SP, et al. Safety and efficacy of minimally invasive percutaneous nephrolithotomy in patients with autosomal dominant polycystic kidney disease[J]. J Endourol, 2014, 28(1): 17-22.
[6]	Singh V, Sinha RJ, Gupta DK. Percutaneous nephrolithotomy in autosomal dominant polycystic kidney disease: is it different from percutaneous nephrolithotomy in normal kidney?[J]. Current urology, 2013, 7(1): 7-13.
[7]	Tan YK, Cha DY, Gupta M. Management of stones in abnormal situations[J]. Urol Clin North Am, 2013, 40(1): 79-97.
[8]	Umbreit EC, Childs MA, Patterson DE, et al. Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney disease[J]. J Urol, 2010, 183(1): 183-187.
[9]	Ozkok A, Akpinar TS, Tufan F, et al. Clinical characteristics and predictors of progression of chronic kidney disease in autosomal dominant polycystic kidney disease: a single center experience[J]. Clin Exp Nephrol, 2013, 17(3): 345-351.
[10]	Zhang J, Zhang J, Xing N. Polycystic kidney disease with renal calculi treated by percutaneous nephrolithotomy: a report of 11 cases[J]. Urol Int, 2014, 92(4): 427-432.
[11]	张成龙, 齐忠权. 尿路结石现代治疗方法的探讨[J]. 中华腔镜泌尿外科杂志(电子版), 2015, 9(1): 59-62.
[12]	Al-Kandari AM, Shoma AM, Eraky I, et al. Percutaneous nephrolithotomy for management of upper urinary tract calculi in patients with autosomal dominant polycystic kidney disease[J]. Urology, 2009, 74(2): 273-277.
[13]	Srivastava A, Bansal R, Srivastava A, et al. Percutaneous nephrolithotomy in polycystic kidney disease: is it safe and effective?[J]. Int Urol Nephrol, 2012, 44(3): 725-730.
[14]	杨炜青, 李逊, 何永忠, 等. 输尿管软镜与微创经皮肾镜治疗多囊肾合并肾结石的疗效比较[J]. 中华腔镜泌尿外科杂志(电子版）, 2016, 10(3): 5-8.
[15]	王少刚, 余虓. 经皮肾镜碎石取石术的现状与进展[J]. 中华腔镜泌尿外科杂志(电子版), 2016, 10(3): 1-4.
[16]	余伟民, 曹君, 阮远, 等. 超声引导"经肾盏穹窿-盏颈轴线两步穿刺法"建立经皮肾通道[J]. 中华腔镜泌尿外科杂志(电子版), 2016, 10(3): 9-12.
[17]	Singla M, Srivastava A, Kapoor R, et al. Aggressive approach to staghorn calculi-safety and efficacy of multiple tracts percutaneous nephrolithotomy[J]. Urology, 2008, 71(6): 1039-1042.

组别	血红蛋白（g/L）	血肌酐（μmol/L）
术前	120±24	292±51
术后	104±21	220±34
t值	5.727	2.388
P值	<0.001	<0.025

组别	血红蛋白（g/L）	血肌酐（μmol/L）
术前	120±24	292±51
术后	104±21	220±34
t值	5.727	2.388
P值	<0.001	<0.025

Please choose a citation manager

Content to export